1 / 33

Chondrosarcoma of the Pelvis Prognostic Factors and Survival Analysis at 10-20 Years

Chondrosarcoma of the Pelvis Prognostic Factors and Survival Analysis at 10-20 Years. Matthew J. Seidel, MD Patrick P. Lin, MD Valerae O. Lewis, MD Christopher P.Cannon, MD Alan W. Yasko, MD. Literature. Goal of Study.

balin
Download Presentation

Chondrosarcoma of the Pelvis Prognostic Factors and Survival Analysis at 10-20 Years

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chondrosarcoma of the PelvisPrognostic Factors and Survival Analysis at 10-20 Years Matthew J. Seidel, MD Patrick P. Lin, MD Valerae O. Lewis, MD Christopher P.Cannon, MD Alan W. Yasko, MD

  2. Literature

  3. Goal of Study • Define long-term oncologic outcome and prognostic factors for chondrosarcoma arising in the pelvic bones

  4. Study Design • Pelvic chondrosarcoma • Surgically treated with curative intent • Minimum 5 year f/u for living patients • 5 year potential f/u for deceased patients • Exclusion: • Sacral epicenter • Recurrent presentation • Metastatic presentation • Prior resection/surgery (other than biopsy)

  5. Data Collection • Retrospective medical record review including operative, pathology, and radiology reports • Demographics • Tumor grade, size, location, physical characteristics • Surgical type and margins • Timing and location of local recurrence and metastasis • Long-term data from clinical follow-up, phone call, or letter

  6. Statistics • Kaplan-Meier survival • Disease-specific survival • Local recurrence-free survival • Distant relapse-free survival • Log rank (determine difference between KM curves) • Chi-square or Fisher’s exact test

  7. 101 Patients • Collection period: 1948-2000 • Follow-up: 5 to 45 years • Overall median 6 year follow-up • Living patients: median 13 year follow-up • 31 female, 70 male

  8. Overall Survival • Status At Last Follow-up • 41 NED • 1 AWD • 45 DOD • 13 DOC • 1 DUC

  9. Grade • 34 Low • 24 Intermediate • 27 High • 16 Dedifferentiated

  10. Epicenter • Ilium: 57 • Pubis: 24 • Acetabulum: 10 • Ischium: 10

  11. Tumor Characteristics • Mean Size: 18.5 cm • Range 3 to 25 cm • Extra-osseous extension in 91 (90%)

  12. Surgical • Surgery Type • Amputation: 37 • Limb salvage: 64 • Surgical Margins • Negative: 56 • Positive: 42 • Not Specified: 3

  13. Disease-Specific Survival

  14. Disease-Specific Survival

  15. DSS: Prognostic Variables

  16. Effect of LR On DSS • Significant decrease in survival for patients with LR • P=.007

  17. Effect of LR On DSSLow Grade • Significant survival difference • P=.003

  18. Effect of LR On DSSIntermediate Grade • Marginal significance • P=.08

  19. Effect of LR On DSSHigh Grade • Not Significant • P=0.42

  20. Results – Local Recurrence • 35 Local Recurrences • Mean time 29 months • Range 3 to 120 months • 91% (32/35) occurred within five years • 3 Local Recurrence after five years • 84 months (low-grade) • 108 months (intermediate-grade) • 120 months (low-grade)

  21. Results – Local Recurrence • 68% of LR (23/34) associated with positive resection margins

  22. Local Recurrence-Free Survival

  23. LR – Prognostic Variables

  24. Results - Metastasis • 28 Metastasis • Mean time 22 months • Range 1-114 months • Location • Lung most common (27) • Other locations: liver (4), brain (2), spine (2), kidney (1), heart (1), pericardium (1), humerus (1), lymph node (1), scalp (1)

  25. Results - Metastasis • 93% (26/28) metastasis occurred in first four years • Two metastasis occurred after four years • 74 months (low-grade; LR at 23, 36, 41 months) • 114 months (intermediate-grade; LR at 108 months)

  26. Results - Metastasis • 26/28 (93%) DOD at last follow-up • Median time 9 months • 2/28 (7%) • DOC (1): NED 5 years after wedge resection at 24 mo • AWD(1): alive 4 years, wedge resection pending • Metastasis has a significant negative effect on DSS (p<.0001)

  27. Distant Relapse-Free Survival

  28. DR-Prognostic Variables

  29. Study Limitations • Diminishing number of patients at 20 years • 39% >10 yr f/u • 17% >20 yr f/u • Changes in mode and quality of radiographic imaging over study period • Vagaries of histological grading • Limited long-term radiographic imaging

  30. Conclusions • Long term follow-up data show LR or metastasis can occur beyond five years • No first LR or metastasis was seen after 10 years

  31. Conclusions • Local Recurrence has a significant negative effect on long term survival • Most pronounced for low and intermediate grade tumors. • Metastasis overwhelmingly resulted in death

  32. Conclusions • Significant prognostic factors at late follow-up are unchanged from short-term follow-up data • Disease-specific survival • Local recurrence-free survival • Distant relapse-free survival

  33. Conclusions • Evidence-based post-operative surveillance strategy should include at least 10 year follow-up after initial resection

More Related